Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.41 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 6/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388419 | 0.81 | KDM4E (0.43) | CHRNA10CHRNA9KDM4ETP53CTSS | |
| SCHEMBL1742050 | 0.80 | USP2 (0.49) | KDM4EMEN1 | |
| SCHEMBL6134966 | 0.79 | KDM4E (0.43) | CHRNA10CHRNA9KDM4ETP53CTSS | |
| SCHEMBL1743458 | 0.76 | HPGD (0.42) | MEN1NPSR1 | |
| SCHEMBL381688 | 0.75 | KCNH2 (0.50) | CHRNA10CHRNA9KDM4ETP53HRH3 | |
| SCHEMBL12126935 | 0.74 | KDM4E (0.53) | CHRNA10CHRNA9KDM4ETP53HTR7 | |
| SCHEMBL22848101 | 0.72 | SIGMAR1 (0.52) | KDM4ETP53HTR7HRH3MEN1 | |
| SCHEMBL22848081 | 0.72 | SIGMAR1 (0.52) | KDM4ETP53HTR7HRH3MEN1 | |
| SCHEMBL22848077 | 0.72 | SIGMAR1 (0.52) | KDM4ETP53HTR7HRH3MEN1 | |
| SCHEMBL376293 | 0.72 | CHRNA10 (0.40) | CHRNA10CHRNA9KDM4ETP53HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765778-B1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-7585858-B2 | N-sulfonylcarboximidamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | CHRNA10 4259/4885CHRNA9 4345/4885KDM4E 1408/4885 |
| US-20050272744-A1 | N-sulfonylcarboximidamide apoptosis promoters | BAX, BCL2, BAD | CHRNA10 4259/4885CHRNA9 4345/4885KDM4E 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.